SCHEDULE: Vivo Opportunity Discloses Aclaris Therapeutics Stake
Schedule 13G Amendment
Vivo Opportunity Fund Holdings and related entities report a combined beneficial ownership of approximately 4.8% in Aclaris Therapeutics, Inc.
Summary
- Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. filed an amendment to their Schedule 13G regarding their holdings in Aclaris Therapeutics, Inc.
- The reporting persons collectively hold 6,666,666 shares of common stock.
- Vivo Opportunity Fund Holdings, L.P. holds 5,966,370 shares, representing 4.3% of the outstanding common stock.
- Vivo Opportunity Cayman Fund, L.P. holds 700,296 shares, representing 0.5% of the outstanding common stock.
- The total ownership percentage is based on 139,663,680 shares outstanding as of April 30, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory disclosure indicating stable institutional interest without immediate strategic shifts.
Positives
- Institutional investment firm maintains a significant position in the issuer, signaling continued interest in the company's equity.
Negatives
- The reporting entities hold less than 5% of the total outstanding shares, which may limit their influence on corporate governance compared to major institutional holders.
Risks
- Market volatility affecting the value of the investment.
- Potential for future dilution if the issuer issues additional shares.
Future Outlook
The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that Schedule 13G filings by investment firms in the biotechnology sector are standard practice for passive investors, reflecting ongoing portfolio management rather than activist intent.
Comparison to Industry Standards
- The filing follows standard SEC disclosure requirements for institutional investors holding significant but non-controlling interests in publicly traded biotech companies.
Stakeholder Impact
- Provides transparency to shareholders regarding the concentration of ownership by institutional entities.
Next Steps
- Continued monitoring of the issuer's share price and future regulatory filings.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of event requiring the filing of this statement. |
| 04/30/2026 | Date used for total shares outstanding calculation. |
| 05/07/2026 | Date of the Issuer's Quarterly Report on Form 10-Q. |
| 05/12/2026 | Date of signature and filing of the Schedule 13G amendment. |
Keywords
Aclaris Therapeutics, Schedule 13G, Vivo Opportunity, Beneficial Ownership, Biotech Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.